Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Gains from Sales and Divestitures (2017 - 2025)

Iradimed (IRMD) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $4813.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures fell 91.13% to $4813.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $4813.0, a 91.13% decrease, with the full-year FY2024 number at $4813.0, down 91.13% from a year prior.
  • Gains from Sales and Divestitures was $4813.0 for Q4 2024 at Iradimed, down from $54282.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $139890.0 in Q3 2020 to a low of $4813.0 in Q4 2024.
  • A 5-year average of $57057.5 and a median of $47520.0 in 2022 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 527.61% in 2021, then plummeted 91.13% in 2024.
  • Iradimed's Gains from Sales and Divestitures stood at $9345.0 in 2020, then surged by 527.61% to $58650.0 in 2021, then plummeted by 30.51% to $40758.0 in 2022, then soared by 33.18% to $54282.0 in 2023, then tumbled by 91.13% to $4813.0 in 2024.
  • Per Business Quant, the three most recent readings for IRMD's Gains from Sales and Divestitures are $4813.0 (Q4 2024), $54282.0 (Q4 2023), and $40758.0 (Q4 2022).